Suppliers and packagers for STROMECTOL

STROMECTOL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Merck Sharp Dohme	STROMECTOL	ivermectin	TABLET;ORAL	050742	NDA	Merck Sharp & Dohme LLC	0006-0032-01	2 BLISTER PACK in 1 CARTON (0006-0032-01) / 10 TABLET in 1 BLISTER PACK	1996-11-22
Merck Sharp Dohme	STROMECTOL	ivermectin	TABLET;ORAL	050742	NDA	Merck Sharp & Dohme LLC	0006-0032-20	2 BLISTER PACK in 1 CARTON (0006-0032-20) / 10 TABLET in 1 BLISTER PACK	1996-11-22

Suppliers for the Pharmaceutical Drug: Stromectol (Ivermectin)

Last updated: July 30, 2025

Introduction

Stromectol, the brand name for ivermectin, is an anthelmintic medication primarily used to treat parasitic infections such as onchocerciasis (river blindness), strongyloidiasis, and other helminthic infestations. Originally developed by Merck & Co., ivermectin has gained widespread global acceptance due to its efficacy, safety profile, and affordability. The supply chain for Stromectol involves a complex network of manufacturers, distributors, and regulatory bodies. This report provides a comprehensive analysis of the key suppliers and manufacturing landscape for Stromectol, highlighting global production centers, licensing agreements, and market dynamics.

Global Manufacturing Landscape of Ivermectin

Original Developer and Patent Status

Merck & Co. introduced ivermectin to the market in the late 1980s after its discovery in the 1970s. Since patent expiry around 1999, generic manufacturers have proliferated, significantly expanding the global supply. The loss of patent protection has led to increased competition, which has improved accessibility, especially in regions with limited healthcare budgets.

Primary Manufacturing Countries

The primary countries involved in ivermectin production include India, China, the United States, and European nations. India and China dominate the manufacturing landscape due to their robust pharmaceutical industries and lower production costs.

Leading Suppliers and Manufacturers

1. Macleods Pharmaceuticals (India):

   • One of the largest producers of generic ivermectin.
   • Supplies to numerous global markets, including Africa, Asia, and Latin America.
   • Website: Macleods Pharmaceuticals

2. Sun Pharmaceuticals (India):

   • Produces ivermectin as part of its extensive portfolio of generic medicines.
   • Regulatory approvals in multiple countries facilitate broad distribution.

3. Hetero Labs (India):

   • Significant producer involved in the bulk manufacturing of ivermectin.
   • Active in both domestic and international markets.

4. Zydus Cadila (India):

   • Manufactures ivermectin for various indications and markets.
   • Emphasizes quality control and compliance with international standards.

5. Cipla (India):

   • Supplies ivermectin tablets globally.

6. Medi-Chem (India):

   • Produces ivermectin formulations for global markets.

7. By-Health (China):

   • Emerging supplier focusing on export markets with competitive pricing.

Additional Notable Suppliers

• United States and European Union:
  • Smaller-scale production primarily involves pharmaceutical companies with regulatory approvals for domestic supply.
  • Companies include Pfizer and other contract manufacturing organizations (CMOs) involved in licensing and distribution.

Regulatory Landscape and Licensing Agreements

Many generic manufacturers operate under sublicenses or face regulatory approvals from agencies such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or national regulators in their target markets. Regulatory barriers significantly influence supply chain dynamics, with some suppliers obtaining Emergency Use Authorizations (EUAs) due to ivermectin's potential role in off-label COVID-19 treatments.

Market Dynamics and Supply Chain Considerations

Global Demand Fluctuations

• Onchocerciasis and Parasitic Infections: Stable demand driven by endemic regions in Africa, Latin America, and Southeast Asia.
• COVID-19 Pandemic: Surge in off-label demand for ivermectin, leading to temporary shortages and increased scrutiny on supply chain robustness.

Supply Chain Challenges

• Quality Control: Validation of manufacturing standards across different countries remains critical to ensure safety and efficacy.
• Intellectual Property (IP): Post-patent expiry has facilitated increased manufacturing, but licensing agreements still influence market access.
• Raw Material Availability: Procurement of active pharmaceutical ingredients (APIs) like ivermectin's core compounds faces challenges related to geopolitical issues and raw material shortages.

Efforts to Increase Production

• WHO and international health agencies have coordinated with manufacturers to double or triple ivermectin production, addressing both neglected tropical disease treatment and emerging demands.
• Some suppliers have entered into public-private partnerships or secured funding from agencies like the Global Fund or PAHO.

Major Suppliers’ Certifications and Quality Standards

• Certifications such as Good Manufacturing Practice (GMP), ISO standards, and compliance with WHO prequalification are essential benchmarks in the supply chain.
• Most leading Indian manufacturers possess WHO GMP compliance, facilitating international procurement, especially by NGOs and governmental agencies.

Future Outlook

The supply landscape for Stromectol (ivermectin) is poised to expand, driven by increased production capacities, regulatory authorizations, and heightened awareness of parasitic diseases. However, the market's stability hinges on maintaining quality standards, managing geopolitical risks, and ensuring equitable access to affordable medication.

---

Key Takeaways

• The global ivermectin supply chain features dominant Indian manufacturers such as Macleods, Sun Pharma, Hetero Labs, Zydus Cadila, and Cipla.
• Post-patent expiry has fostered a competitive environment, increasing the availability of generic ivermectin manufacturers worldwide.
• Supply chain stability depends on quality assurance, raw material access, and regulatory compliance.
• The COVID-19 pandemic temporarily strained supply chains due to surges in demand, prompting increased production efforts.
• International agencies are pivotal in coordinating efforts to scale manufacturing and ensure equitable access.

---

FAQs

1. Who are the leading global suppliers of Stromectol (ivermectin)?
   Leading suppliers include Indian pharmaceutical giants like Macleods Pharmaceuticals, Sun Pharmaceuticals, Hetero Labs, Zydus Cadila, and Cipla, with additional contributions from Chinese manufacturers and regional producers.

2. Is ivermectin manufacturing regulated globally?
   Yes. Manufacturers must adhere to Good Manufacturing Practices (GMP) and obtain relevant regulatory approvals such as WHO prequalification, FDA, or EMA authorizations, ensuring product safety and efficacy.

3. How has the COVID-19 pandemic impacted ivermectin supply?
   The pandemic caused spikes in demand for ivermectin as a potential COVID-19 therapy, leading to temporary shortages and supply chain disruptions. This prompted increased manufacturing commitments and regulatory responses to meet global needs.

4. Are there licensing agreements influencing ivermectin supply?
   Since patent expiry, most generic production occurs without licensing barriers. However, specific formulations or formulations for particular markets may involve licensing or regulatory stipulations.

5. What are the future prospects for ivermectin supply?
   Increased manufacturing capacity, regulatory approvals, and global initiatives targeting parasitic diseases are expected to sustain and grow ivermectin supply. Ensuring quality standards remains vital to maintaining supply integrity.

---

References

[1] WHO. "Prequalification of Medicines Programme." World Health Organization, 2022.
[2] USFDA. "Generic Drug Approvals and Pending Applications." U.S. Food and Drug Administration.
[3] MarketWatch. "Ivermectin Market Analysis & Industry Forecast." 2022.
[4] Pharm Biz. "Indian Pharmaceutical Industry Overview." 2022.
[5] Gilead Science. "Global API Manufacturing and Supply Chain Insights." 2022.